Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers

Circulation

Volumn 95, Issue 9, 1997, Pages 2286-2292

  Noll, Georg ^a,b   Wenzel, René R ^a   De Marchi, Stefano ^a   Shaw, Sidney ^a   Lüscher, Thomas F ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

angiotensin; drugs; nervous system, autonomic; nitroglycerin

Indexed keywords

CAPTOPRIL; ENDOTHELIN 1; ISOSORBIDE DINITRATE; PLACEBO; RENIN; VASODILATOR AGENT;

ADAPTATION; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLD PRESSOR TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL STRESS; MUSCLE INNERVATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; SYMPATHETIC NERVE; SYMPATHETIC TONE; TABLET; VOLUNTEER;

EID: 0030937524     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.9.2286     Document Type: Article

References (57)

1. Wallin BG, Kunimoto MM, Seligen J. Possible genetic influence on strength of human muscle nerve sympathetic activity at rest. Hypertension. 1993;22:282-284.
2. Mark AL, Victor RG, Nerhed C, Wallin BG. Microneurographic studies of the mechanisms of sympathetic nerve responses to static exercise in humans. Circ Res. 1985;57:461-469.
3. Normell LA, Wallin BG. Sympathetic skin nerve activity and skin temperature changes in man. Acta Physiol Scand. 1974;91:417-426.
4. Sanders JS, Ferguson DW. Diastolic pressure determines autonomic responses to pressure perturbation in humans. J Appl Physiol. 1989; 66:800-807.
5. Wallin BG, Frisk-Holmberg M. The antihypertensive mechanism of clonidine in man: evidence against a generalized reduction of sympathetic activity. Hypertension. 1981;3:340-346.
6. Delius W, Hagbarth KE, Hongell A, Wallin BG. General characteristics of sympathetic activity in human muscle nerves. Acta Physiol Scand. 1972;84:65-81.
7. Ferguson DW, Hayes DW, Nifedipine potentiates cardiopulmonary baroreflex control of sympathetic nerve activity in healthy humans: direct evidence from microneurographic studies. Circulation. 1989;80:285-298.
8. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients; direct evidence from sympathetic neural recordings. Circulation. 1989;80:65-77.
9. Biaggioni I, Killian TJ, Mosqueda GR, Rohertson RM, Rohertson D, Adenosine increases sympathetic nerve traffic in humans, Circulation. 1991;83:1668-1675.
10. Hoffman RP, Sinkey CA, Kienzle MG, Anderson EA. Muscle sympathetic nerve activity is reduced in IDDM before overt autonomic neuropathy, Diabetes. 1993;42:375-380.
11. Anderson EA, Mark AL. The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. Hypertension. 1993;21:136-141.
12. Matsukawa T, Gotoh E, Minamisawa K, Kihura M, Ueda S, Shionoiri H, Ishii M. Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol. 1991;261:R690-R696.
13. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kuho SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82: 1724-1729.
14. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M. Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial: the SAVE Investigators. N Engl J Med. 1992;327:669-677.
15. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD Investigators, N Engl J Med. 1991;325:293-302.
16. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD Investigators. N Engl J Med. 1992;327:685-691.
17. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure: the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821-828.
18. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet. 1994;343:1115-1122.
19. ISIS-4, A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction: IS1S-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669-685.
20. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality: CONSENSUS Trial Study Group, Circulation. 1990;82:1730-1736.
21. Victor RG, Pryor SL, Secher NH, Mitchell JH. Effects of partial neuromuscular blockade on sympathetic nerve responses to static exercise in humans, Circ Res. 1989;65:468-476.
22. Beaulieu M, Lacourciere Y, Cleroux J. Unchanged neurogenic vasoconstrictor response after exercise during angiotensin converting enzyme inhibition with fosinopril. Am J Hypertens. 1994;7:763-766.
23. Fahy G, Deb B, Robinson K, Graham I. The effects of lisinopril on serum catecholamine concentrations both at rest and on exercise in patients with congestive cardiac failure: a double blind, placebo controlled, parallel group study, Ir Med J. 1993;86:134-135.
24. Giannattasio C, Cattaneo BM, Omboni S, Seravalle G, Bolla G, Turolo L, Morganti A, Grassi G, Zanehetti A, Maneis G. Sympathomoderating influence of benazepril in essential hypertension. J Hypertens. 1992;10:373-378.
25. McGrath BP, Amolda LF. Enalapril reduces the catecholamine response to exercise in patients with heart failure. Eur J Clin Pharmacol. 1986;30:485-487.
26. Minatoguchi S, Ito H, Koshiji M, Masao K, Hirakawa S, Majewski H. Enatapril decreases plasma noradrenaline levels during the cold presser test in human hypertensives, Clin Exp Pharmacol Physiol. 1992;19:279-282.
27. Yunagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
28. Yanagisawa M, Masaki T. Molecular biology and biochemistry of the endothelins. Trends Pharmacol Sci. 1989;10:374-378.
29. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta: inhibition of endotheltum-derived nitric oxide. J Clin Invest. 1990;85:587-590.
30. Lüscher TF, Oemar BS, Boulanger CM, Hahn AW. Molecular and cellular biology of endothelin and its receptors: part I J Hypertens. 1993;11:7-11.
31. Cernacek P, Stewart DJ, Immunoreactive endothelin in human plasma; marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun. 1989;161:562-567.
32. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates, with the extent of pulmonary hypertension in patients with chronic congestive heart failure, Circulation, 1992;85: 504-509.
33. Noll G, Tschudi MR, Novosel D, Lüscher TF, Activity of the L-arginine/nitirc oxide pathway and endothelin-1 in experimental heart failure, J Cardiovasc Pharmacol. 1994;23:916-921.
34. Stewart DJ, Kubac G, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18:38-43.
35. Tomoda H. Plasma endothelin-1 in acute myocardial infarction with heart failure, Am Heart J. 1993;125:667-672.
36. Lerman A, Edwards BS, Hallen JW, Heublein DM, Sandherg SM, Burnett JJ, Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis, N Engl J Med. 1991;325:997-1001.
37. Lüscher TF, Sen BG, Bühler FR. Potential role of endothelin in hypertension: controversy on endothelin in hypertension. Hypertension, 1993;21:752-757.
38. Omland T, Terje Lie R, Aakvaug A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89:1573-1579.
39. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JJ. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc. 1992;67:719-724.
40. Fyhrquist F, Saijonmaa O, Metsarinne K, Tikkaner I, Rosenlof K, Tikkanen T, Raised plasma endothelin-l concentration following cold pressor test. Biochem Biophys Res Commun. 1990;169:217-221.
41. Victor RG, Leimbach WJ, Seals DR, Wallin BG, Mark AL. Effects of the cold pressor test an muscle sympathetic nerve activity in humans. Hypertension, 1987;9:429-436.
42. Fagius J, Karhuvaara S. Sympathetic activity and blood pressure increases with bladder distension in humans. Hypertension. 1989;14:511-517.
43. Delius W, Hagbarth KE, Hongell A, Wallin BG. Manoeuvres affecting sympathetic outflow in human muscle nerves. Acta Physiol Scand. 1972;84:82-94.
44. Anderson EA, Wallin BG, Mark AL. Dissociation of sympathetic nerve activity in arm and leg muscle during mental stress. Hypertension. 1987;9(suppl III):III-114-III-119.
45. Anderson EA, Sinkey CA, Lawton WJ, Mark AL, Elevated sympathetic nerve activity in borderline hypertensive humans; evidence from direct intraneural recordings. Hypertension. 1989;14:177-183.
46. Dohi Y, Luscher TF. Altered intra- and extraluminal effects of 5hydroxytryptamine in hypertensive mesenteric resistance arteries: contribution of the endothelium and smooth muscle. J Cardiavasc Pharmacol. 1991;18:278-284.
47. Goerre S, Wenk M, Bartsch P, Lüscher TF, Niroomand F, Hohenhaus E, Oelz O, Reinhart WH. Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation. 1995;91: 359-364.
48. Haber E, Koerner T, Page LB, Kliman B, Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969;29:1349-1355.
49. Lutz D, Rasper J, Gielsdorf W, Settlage JA, Jaeger H. Automated simultaneous determination of isosorbide dinitrate and its metabolites in plasma by capillary column gas Chromatography. J High Resol Chromatogr Chromatogr Commun. 1984;7:58-65.
50. Bökens H, Foullois M, Müller RF. Determination of total and unchanged captopril in human plasma by high-performance liquid Chromatography. Fresenius Z Anal Chem. 1988;330:431-432.
51. Gruber KA, Callahan MF, Eskridge SS, Central administration of angiotensin II receptor antagonists and arterial pressure regulation: a note of caution. Life Sci. 1992;50:1497-1502.
52. Kannan H, Nakamura T, Jin XJ, Hayashida Y, Yamashita H. Effects of centrally administered angiotensin on sympathetic nerve activity and blood flow to the kidney in conscious rats. J Auton Nerv Syst. 1991;34:201-210.
53. Weekley LB, Angiotensin-II acts centrally to alter renal sympathetic nerve activity and the intrarenal renin-angiotensin system. Cardiovasc Res. 1991;25:353-363.
54. Miyajima E, Yamada Y, Yoshtda Y, Matsukawa T, Shionoiri H, Tochikubo O, Ishii M. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension. 1991;17:1057-1062.
55. Niederberger M, Aubert JF, Nussberger J, Brunner HR, Waeber B. Sympathetic nerve activity in conscious renal hypertensive rats treated with an angiotensin converting enzyme inhibitor or an angtotensin II antagonist. J Hypertens. 1995;13:439-445.
56. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
57. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.